



SGLT2i MRI

Hjärt- och njurprotektion

230131

1


SGLT2 mekanism



- Natrium NHE1
NHE3
- Energiutnyttjande switch Ketoner metabol
- Inflammation "Fasta"


2

EMPAREG 2015



3


EMPEROR HJÄRTSVIKT



4



Studiekonkurrens Hjärtsvikt



5

INTRAGLOMERULÄR TRYCKREGLERING



Afferent / efferent


Macula densa

Na

Adenosin

Prostaglandin E


Renin → *Angiotensin II* → *Aldosteron*




© 2013 Pearson Education, Inc.

6

TUBULOGLOMERULÄR FEEDBACK



7




8

GFR



A Change in eGFR over 192 Wk

EMPAREG outcome



No. at Risk

Placebo	2323	2295	2267	2205	2121	2064	1927	1981	1763	1479	1262	1123	977	731	448
Empagliflozin, 10 mg	2322	2290	2264	2235	2162	2114	2012	2064	1839	1540	1314	1180	1024	785	513
Empagliflozin, 25 mg	2322	2288	2269	2216	2156	2111	2006	2067	1871	1563	1340	1207	1063	838	524

No. in Follow-up Analysis

Total	7020	7020	6996	6931	6864	6765	6696	6651	6068	5114	4443	3961	3488	2707	1703
-------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------

Parallell med ACEI

9


NHE1 / NHE3

Diabetes II


Insulin




Diabetes Activates Proximal Tubular NHE3, Reduces Sodium Delivery to Macula Densa, and Causes Glomerular Hyperfiltration



Insulin Signaling Can Activate NHE and Increase the Risk of Heart Failure




10



11


Fig. 5: Scheme representing the proposed effects of SGLT2 inhibitor on NLRP3 inflammasome activation.

From: [SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease](#)



12



SGLT_i



13


SGLT₂i cardiellt energitnyttjande / SNS

Masterclass




14

SGLT2 SNS



15

JACC




16

Epikardiel fett HFpEF



CENTRAL ILLUSTRATION: Potential Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction

Potential Role of Epicardial Adipose Tissue in Heart Failure With a Preserved Ejection Fraction




Packer, M. J Am Coll Cardiol. 2018;71(20):2360-72.

17




FIGURE 3 Multiple Sites for the Beneficial Effects of SGLT2 Inhibition



Proposed renal mechanisms for increased erythropoietin (EPO) with sodium-glucose cotransporter 2 (SGLT2) inhibitors. Reproduced with

18

”House keeping” Mitokondrier SWITCH*




Nutrient deprivation signaling vs Nutrient surplus signaling

-Ketoner

-SGLT2i direkt

19




20

SGLT2i Alzheimer




Figure 3. Influence of SGLT2 inhibitors on unrestrained activation of mTOR (mechanistic/mammalian target of rapamycin). AMPK-AMP-activated protein kinase, SIRT-Sirtuin.

Fas III Human



21

SGLT2i Alzheimer



22

SGLT2i Additiv /synergi



+ Metformin

+ GLP-1

+ DPP-4

+ ACEI / ARB

+ MRI

spironolakton / eplerone / finerenon

23

Forxiga = Jardiance*

EF 20-60



Väldokumenterat effektiva vid HF*


Snabbt insättande effekt

Oberoende av p-glucos / diabetes


"On top" på RAAS- DPP4-GLP1 + neprilysin inhibition

Njurprotektion

24



25



26

Organprotektion och försiktighet i kliniken



- Implementeras tidigt tillsammans med RAAS blockad
- Diabetes II = Icke diabetes d.v.s generellt vid proteinuriska nefropatier
- Undvik undernutrierade multisyjuka äldre diabetiker Ketoacidosis!!!
- Undvik KAD
- Behandlingsuppehåll på samma sätt som RAAS blockad vid exempelvis gastroenterit
- Vagt diabetes- blodtrycks läkemedel i sig
- Kontraindicerat vid Diabetes I

27

Forxiga = Jardiance*

EF 20-60



Väldokumenterat effektiva vid HF*

Snabbt insättande effekt


Oberoende av p-glucos / diabetes

”On top” på RAAS- DPP4-GLP1 + neprilysin inhibition

Njurprotektion


28

MRAs / MRI



29

FIGURE 3 FIDELIO-DKD and FIGARO-DKD endpoints. ^aKidney failure defined as occurrence of ESKD (initiation of ...



Nephrol Dial Transplant, Volume 37, Issue 6, June 2022, Pages 1014–1023, <https://doi.org/10.1093/ndt/gfaa294>
The content of this slide may be subject to copyright; please see the slide notes for details.



30

MRI

Finerenon

KERENDIA



- *Fri från steroid endokrina effekter*
- *MR specifik*
- *Cardiellt antiinflammatoriska effekter*
- *Mindre hyperkalemi*

*Hjärtsvikt studier
kommer.....*

- *FASS : Diabetes II +CKD3 - CKD4 + albuminuri* *FIDELIO FIGARO*

31



32